XBIO
Xenetic Biosciences, Inc.
There isn't enough reported data to score XBIO yet.
XBIO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Unavailable |
XBIO's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
XBIO PE Valuation
XBIO has no meaningful PE right now: it lost money over the past year.
XBIO Forward outlook
There aren't enough analyst estimates for XBIO to show an outlook.
XBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.54 | +$0.51 |
| Q2 2026 | -$1.15 | +$0.85 |
| Q1 2026 | -$1.19 | +$1.19 |
| Q4 2025 | -$1.58 | +$0.99 |
| Q3 2025 | -$2.05 | +$0.57 |
| Q2 2025 | -$2.00 | +$1.03 |
| Q1 2025 | -$2.38 | +$0.51 |
| Q4 2024 | -$2.57 | +$0.14 |
XBIO is still losing money, but far less than before: $1.54 per share over the past year, against $17.00 at its worst in late 2020.
XBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $725.3K | -29% |
| Q2 2026 | $660.6K | +12% |
| Q1 2026 | $806.9K | +36% |
| Q4 2025 | $766.3K | +18% |
| Q3 2025 | $1M | +67% |
| Q2 2025 | $589.9K | -19% |
| Q1 2025 | $593.3K | +16% |
| Q4 2024 | $648.8K | -3.4% |
XBIO's revenue fell from its 2025 peak and has held roughly level since: $725,257 last quarter, down 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -240% | -187 points |
| Q2 2026 | -147% | -24 points |
| Q1 2026 | -62% | +97 points |
| Q4 2025 | -81% | +88 points |
| Q3 2025 | -53% | +28 points |
| Q2 2025 | -123% | +61 points |
| Q1 2025 | -159% | +90 points |
| Q4 2024 | -169% | +18 points |
XBIO's operating margin was −240% last quarter, down 187 points from the same quarter a year ago.
XBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$662.1K | -$3.9K |
| Q2 2026 | -$875.5K | -$491.7K |
| Q1 2026 | -$536.4K | +$465.5K |
| Q4 2025 | -$242.7K | +$431.3K |
| Q3 2025 | -$658.2K | -$199.2K |
| Q2 2025 | -$383.8K | +$141.3K |
| Q1 2025 | -$1M | +$157.5K |
| Q4 2024 | -$674K | +$119K |
XBIO has burned cash in almost every quarter: −$2M over the past year, against −$3M the year before.
XBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +48.8K shares |
| 1 year | +52% | +801K shares |
| 3 years | +54% | +818K shares |
| 5 years | +168% | +1.5M shares |
| Available history | +276% | +1.7M shares |
XBIO has 2M diluted shares, up 52% from a year ago.
XBIO Net Leverage
XBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
XBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 8.3 | Oversold |
XBIO's weekly RSI is 37 (neutral) and its Stochastic is 8 (oversold).
XBIO PE vs Healthcare Sector
XBIO has no meaningful PE right now: it lost money over the past year.
XBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.01 | 17% below |
| 20 week MA | $2.74 | 39% below |
| 50 week MA | $2.72 | 39% below |
| 100 week MA | $3.06 | 46% below |
| 200 week MA | $3.54 | 53% below |
XBIO is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
XBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.3 | $21.9 | +53% |
| 2021 | $21.9 | $14.4 | -34% |
| 2022 | $14.4 | $3.10 | -78% |
| 2023 | $3.10 | $3.45 | +11% |
| 2024 | $3.45 | $4.11 | +19% |
| 2025 | $4.11 | $2.08 | -49% |
| 2026 YTD | $2.08 | $1.66 | -20% |
XBIO has finished lower in three of the last six years. It's down 20% so far in 2026.